← Back to headlines
Cytokinetics Targets MYQORZO Share and Plans nHCM sNDA
Cytokinetics aims for over 50% MYQORZO new-to-brand share by the end of 2026 and plans a New Drug Application (sNDA) for nHCM in Q4.
7 Aug, 02:55 — 7 Aug, 02:55
Sources
Showing 1 of 1 sources
